Cara Therapeutics Inc. (NASDAQ:CARA) traded up 4.1% during trading on Wednesday . The company traded as high as $5.05 and last traded at $5.03, with a volume of 238,466 shares traded. The stock had previously closed at $4.83.

A number of equities research analysts have commented on the stock. Zacks Investment Research lowered shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, July 11th. Needham & Company LLC restated a “buy” rating on shares of Cara Therapeutics in a research report on Friday, May 6th. Piper Jaffray Cos. restated an “overweight” rating and set a $23.00 target price on shares of Cara Therapeutics in a research report on Saturday, April 23rd. Cantor Fitzgerald restated a “buy” rating on shares of Cara Therapeutics in a research report on Wednesday, April 20th. Finally, Canaccord Genuity restated a “buy” rating and set a $30.00 target price on shares of Cara Therapeutics in a research report on Friday, May 6th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $21.21.

The stock’s market cap is $136.96 million. The firm’s 50 day moving average price is $5.26 and its 200 day moving average price is $6.95.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. The business earned $0.01 million during the quarter, compared to the consensus estimate of $0.03 million. During the same quarter last year, the company earned ($0.21) EPS. The firm’s revenue for the quarter was down 98.6% compared to the same quarter last year. Analysts predict that Cara Therapeutics Inc. will post ($1.72) earnings per share for the current fiscal year.

Other hedge funds and institutional investors have recently bought and sold shares of the company. GSA Capital Partners LLP increased its position in Cara Therapeutics by 29.5% in the fourth quarter. GSA Capital Partners LLP now owns 91,073 shares of the biopharmaceutical company’s stock valued at $1,535,000 after buying an additional 20,754 shares during the last quarter. EAM Investors LLC increased its position in Cara Therapeutics by 97.3% in the fourth quarter. EAM Investors LLC now owns 109,599 shares of the biopharmaceutical company’s stock valued at $1,848,000 after buying an additional 54,046 shares during the last quarter. Finally, Jennison Associates LLC increased its position in Cara Therapeutics by 0.3% in the fourth quarter. Jennison Associates LLC now owns 656,467 shares of the biopharmaceutical company’s stock valued at $11,068,000 after buying an additional 2,009 shares during the last quarter.

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.